Bardy Diagnostics, Inc.
https://www.bardydx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Bardy Diagnostics, Inc.
iRhythm Is ‘Encouraged’ By Recent Reimbursement Discussions With Novitas
The company provided another update on its ongoing efforts to secure adequate Medicare reimbursement for long-term continuous cardiac monitoring.
Reimbursement Dispute Between Novitas And iRhythm Hits An Impasse
Local Medicare carrier Novitas raised its reimbursement rates for continuous cardiac monitoring, but iRhythm has concluded the rates are still too low and is preparing to discontinue serving this Medicare segment.
Updated: Reimbursement Questions Jeopardize Hillrom/Bardy Merger
Hillrom is reconsidering its planned $375m acquisition of Bardy Diagnostics because of Novitas' plan to cut Medicare reimbursement for extended cardiac monitoring. Bardy is suing to complete the deal.
Boston Scientific Bets Big On Monitoring; Buys Preventice For Up To $1.25Bn
The deal is the fourth major acquisition in the remote monitoring market in the last five weeks after Philips acquired BioTelemetry and Capsule and Hillrom bought Bardy Diagnostics.
Company Information
- Industry
-
Medical Devices
- Monitoring Equipment & Devices
- Other Names / Subsidiaries
-
- Bardy Diagnostics
- BardyDx
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice